Galanin inhibits insulin secretion and induces hyperglycemia in dogs.
Intravenous administration of galanin into fasted conscious dogs produced a dose-dependent hyperglycemia accompanied by decreases in plasma insulin levels, but with no elevation of plasma glucagon levels. Galanin infusions produced greater parenteral glucose-induced rises in plasma glucose levels along with markedly blunted insulin responses compared with glucose and insulin responses to control glucose infusions. Immediately after cessation of the galanin infusions, elevation of plasma insulin levels occurred in the basal state and after parenteral glucose loading. These results suggest that galanin's hyperglycemic activity is predominantly mediated by a reversible inhibition of insulin secretion.
McDonald
T J
TJ
Dupre
J
J
Tatemoto
K
K
Greenberg
G R
GR
Radziuk
J
J
Mutt
V
V
D000595:Amino Acid Sequence; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004285:Dogs; D005215:Fasting; D019004:Galanin; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism; D005934:Glucagon / Q000097:blood; D006943:Hyperglycemia / Q000097:blood / Q000139:chemically induced*; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D010191:Pancreatic Polypeptide / Q000097:blood; D010455:Peptides / Q000494:pharmacology*
D001786:Blood Glucose; D007328:Insulin; D010455:Peptides; D005749:Gastric Inhibitory Polypeptide; D010191:Pancreatic Polypeptide; D019004:Galanin; D005934:Glucagon